|Summary sheet: TMA-6|
|Psychoactive class||Psychedelic / Stimulant|
|Routes of Administration|
|Selective serotonin re-uptake inhibitors|
|Serotonin-norepinephrine reuptake inhibitors|
2,4,6-Trimethoxyamphetamine (also known as TMA-6) is a lesser-known psychedelic substance of the amphetamine class. It has been reported to produce a complex mixture of stimulant, hallucinogenic and entactogenic effects that distinguish it from other psychedelic phenethylamine derivatives like the 2C-x or DOx series.
TMA-6 has no history of human usage prior to the 1991 publication of its synthesis and pharmacology in the book PiHKAL ("Phenethylamines I Have Known And Loved") by Alexander Shulgin, who called it "one of the most rewarding and pleasurable of the methoxylated amphetamines". Since then it has been regarded as a novelty in the psychedelics community and is made available for sale only rarely by clandestine laboratory operations.
In terms of its subjective effects, it is known for its lack of classic psychedelic visuals compared to other hallucinogenic phenethylamines and is known instead for its unique stimulating body-high and intoxicating headspace.
Anecdotal reports suggest that TMA-6 is unpredictable and dose-sensitive substance that can produce uncomfortable amounts of body load, nausea, overstimulation, and inconsistencies between experiences.
In modern times, TMA-6 is used rarely as a recreational drug and a putative entheogen. It has no documentation of being sold on the streets and is almost exclusively obtainable as an obscure gray area research chemical through the use of online vendors.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
TMA-6, or 2,4,6-trimethoxyamphetamine, is a molecule of the substituted amphetamine class. Amphetamines are substituted phenethylamines, being comprised of a phenyl ring bound to an amino (NH2) group through an ethyl chain and a methyl group bound to the alpha carbon Rα. TMA-6 contains methoxy functional groups CH3O- attached to carbons R2 and R4 and R6 of the amphetamine backbone.
TMA-6's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature which relies on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.
- Stimulation - In terms of its effects on the physical energy levels of the user, TMA-6 is usually considered to be extremely stimulating at levels which do not become overwhelming, resulting in a shakiness and unsteadiness of the hands but encouraging one to move around, run, dance, climb and generally engage in physical activities. In comparison, other more commonly used psychedelics such as psilocin are generally sedating and relaxed.
- Spontaneous tactile sensations - The "body high" of TMA-6 is manifested as somewhat intense in comparison to most classical psychedelics such as LSD. The sensation itself can be described as a constantly present yet somewhat mild energetic pins and needles sensation that encompasses a person’s entire body. It is usually felt over every square inch of the skin, but occasionally manifests itself in the form of a continuously shifting tingling sensation that travels up and down the body in spontaneous waves.
- Tactile enhancement - Feelings of enhanced tactile sensation are consistently present at moderate levels throughout most TMA-6 trips.
- Nausea - Mild to extreme nausea is reported when consumed in moderate to high dosages and either passes once the person has vomited or gradually fades by itself as the peak sets in.
- Vasoconstriction - This effect is usually only present at higher dosages, but can be particularly uncomfortable.
- Bodily control enhancement
- Pupil dilation
- Increased blood pressure
The cognitive effects of TMA-6 are described as powerful mental stimulation along with undertones of intoxication that can increase the connectivity and rate of conceptual thinking without being overwhelming.
The total sum of these cognitive components regardless of the setting generally includes:
- Empathy, love, and sociability enhancement - This component is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are weaker and sharper than those found on substances such as MDMA and 2C-B, but still can elevate one's mood.
- Analysis enhancement
- Thought acceleration
- Time distortion
- Novelty enhancement
- Immersion enhancement
- Conceptual thinking
- Thought connectivity
- Emotion enhancement
- Increased music appreciation
- Personal bias suppression
- Memory suppression
- Increased libido
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational TMA-6 use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because TMA-6 has very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried TMA-6 suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
Tolerance and addiction potential
Though largely unstudied TMA-6 is largely considered to be not habit-forming and the desire to use it can actually decrease with consumption. It is most often self-regulating.
Tolerance to the effects of TMA-6 are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). TMA-6 presents cross-tolerance with all psychedelics, meaning that after the consumption of TMA-6 all psychedelics and stimulants will have a reduced effect.
Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
- Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.
- Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.
Serotonin syndrome risk
Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.
- MAOIs such as syrian rue, banisteriopsis caapi, 2C-T-7, αMT, phenelzine, selegiline, and moclobemide
- Serotonin releasers such as MDMA, 4-FA, methamphetamine, methylone and αMT
- Selective serotonin re-uptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as tramadol and DXM
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Germany: TMA-6 is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- Switzerland: TMA-6 is not specifically named, although it can be considered an ether analog of an ether analog of PMA, which would make it illegal according to Buchstabe C.
- Turkey: TMA-6 is a classed as drug and is illegal to possess, produce, supply, or import. 
- Responsible use
- Research chemicals
- Substituted amphetamines
- Alexander Shulgin
- Trimethoxyamphetamine (Wikipedia)
- TMA-6 (PiHKAL / Isomer Design)
- The Big & Dandy TMA Series Thread (Bluelight)
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
- Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
- "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.